| scholarly article | Q13442814 |
| P50 | author | Brindusa Tiperciuc | Q83234141 |
| Radu Tamaian | Q86416180 | ||
| Cristina Nastasă | Q86416182 | ||
| P2093 | author name string | Ovidiu Oniga | |
| P2860 | cites work | RAS-MAPK pathway epigenetic activation in cancer: miRNAs in action | Q26773479 |
| Beyond BRAF: where next for melanoma therapy? | Q27006853 | ||
| ZINC--a free database of commercially available compounds for virtual screening | Q27656255 | ||
| Small-molecule ligands bind to a distinct pocket in Ras and inhibit SOS-mediated nucleotide exchange activity | Q27678097 | ||
| K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions | Q27680654 | ||
| In situ selectivity profiling and crystal structure of SML-8-73-1, an active site inhibitor of oncogenic K-Ras G12C | Q27684047 | ||
| Biochemical and Structural Analysis of Common Cancer-Associated KRAS Mutations | Q27700955 | ||
| AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading | Q27860652 | ||
| Mutations of the BRAF gene in human cancer | Q27860760 | ||
| Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings | Q27861111 | ||
| Calculating an optimal box size for ligand docking and virtual screening against experimental and predicted binding pockets | Q27902293 | ||
| Covalent docking of large libraries for the discovery of chemical probes | Q28250319 | ||
| Computation of octanol-water partition coefficients by guiding an additive model with knowledge | Q28256418 | ||
| Designing drugs to avoid toxicity | Q28305269 | ||
| Designing focused chemical libraries enriched in protein-protein interaction inhibitors using machine-learning methods | Q28473098 | ||
| MAP kinase signalling pathways in cancer | Q29615542 | ||
| New Thiazolyl-triazole Schiff Bases: Synthesis and Evaluation of the Anti-Candida Potential. | Q51307888 | ||
| High throughput kinetic profiling approach for covalent binding to peptides: application to skin sensitization potency of Michael acceptor electrophiles. | Q51829931 | ||
| ESOL: estimating aqueous solubility directly from molecular structure. | Q51997302 | ||
| An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling. | Q54545577 | ||
| Prediction of drug absorption using multivariate statistics | Q73126791 | ||
| Generation of a set of simple, interpretable ADMET rules of thumb | Q80581967 | ||
| Prevalence and heterogeneity of KRAS, BRAF, and PIK3CA mutations in primary colorectal adenocarcinomas and their corresponding metastases | Q82657420 | ||
| Synthesis of new N-substituted 5-arylidene-2,4-thiazolidinediones as anti-inflammatory and antimicrobial agents | Q86769142 | ||
| A review of the electrophilic reaction chemistry involved in covalent protein binding relevant to toxicity | Q37910202 | ||
| Chemical predictive modelling to improve compound quality | Q38167262 | ||
| Drug discovery considerations in the development of covalent inhibitors | Q38169313 | ||
| The Emerging Role of NRAS Mutations in Colorectal Cancer Patients Selected for Anti-EGFR Therapies | Q38206575 | ||
| Thiazolidine-2,4-diones as multi-targeted scaffold in medicinal chemistry: Potential anticancer agents | Q38273923 | ||
| Treatment of NRAS-mutant melanoma. | Q38386344 | ||
| Synthesis and cytotoxicity evaluation of aryl triazolic derivatives and their hydroxymethine homologues against B16 melanoma cell line. | Q38758589 | ||
| MAP Kinase Inhibition Promotes T Cell and Anti-tumor Activity in Combination with PD-L1 Checkpoint Blockade | Q38788877 | ||
| Direct small-molecule inhibitors of KRAS: from structural insights to mechanism-based design | Q38911598 | ||
| KRAS, NRAS and BRAF mutations in colorectal cancer and melanoma | Q39078976 | ||
| Design of a general-purpose European compound screening library for EU-OPENSCREEN. | Q39156659 | ||
| Structural characterization of NRAS isoform 5 | Q40413262 | ||
| Genomic alterations in spontaneous and carcinogen-induced murine melanoma cell lines | Q40595725 | ||
| Superoxide anion-dependent Raf/MEK/ERK activation by peroxisome proliferator activated receptor gamma agonists 15-deoxy-delta(12,14)-prostaglandin J(2), ciglitazone, and GW1929. | Q40722386 | ||
| Using the Golden Triangle to optimize clearance and oral absorption | Q43282932 | ||
| Frequency and type of KRAS mutations in routine diagnostic analysis of metastatic colorectal cancer | Q43292375 | ||
| Peroxisome proliferator-activated receptors modulate K-Ras-mediated transformation of intestinal epithelial cells. | Q44010464 | ||
| Broad coverage of commercially available lead-like screening space with fewer than 350,000 compounds | Q45846909 | ||
| Rules for identifying potentially reactive or promiscuous compounds | Q46634285 | ||
| Synthesis and aldose reductase inhibitory activity of some new chromonyl-2,4-thiazolidinediones | Q46723087 | ||
| e-Drug3D: 3D structure collections dedicated to drug repurposing and fragment-based drug design. | Q47993030 | ||
| The clinical significance of BRAF and NRAS mutations in a clinic-based metastatic melanoma cohort. | Q48005942 | ||
| A topological substructural molecular design approach for predicting mutagenesis end-points of alpha, beta-unsaturated carbonyl compounds. | Q50051746 | ||
| New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays | Q29615588 | ||
| A comprehensive survey of Ras mutations in cancer | Q30416821 | ||
| How does the quality of phospholipidosis data influence the predictivity of structural alerts? | Q30838665 | ||
| Property distribution of drug-related chemical databases. | Q30855791 | ||
| Rationalizing the chemical space of protein-protein interaction inhibitors | Q30962611 | ||
| Is there a difference between leads and drugs? A historical perspective | Q31017131 | ||
| An empirical process for the design of high-throughput screening deck filters. | Q33244050 | ||
| Lessons learnt from assembling screening libraries for drug discovery for neglected diseases | Q33309109 | ||
| FAF-Drugs2: free ADME/tox filtering tool to assist drug discovery and chemical biology projects | Q33371792 | ||
| Covalent modifiers: an orthogonal approach to drug design | Q33406988 | ||
| KRAS mutations in primary colorectal cancer tumors and related metastases: a potential role in prediction of lung metastasis | Q33519564 | ||
| Immunomic, genomic and transcriptomic characterization of CT26 colorectal carcinoma | Q33556731 | ||
| Probing the probes: fitness factors for small molecule tools | Q34001269 | ||
| Strategies for discovering and derisking covalent, irreversible enzyme inhibitors | Q34023143 | ||
| Molecular properties that influence the oral bioavailability of drug candidates | Q34130727 | ||
| Nonleadlikeness and leadlikeness in biochemical screening | Q34174693 | ||
| Ras in cancer and developmental diseases | Q34202697 | ||
| The PDBbind database: collection of binding affinities for protein-ligand complexes with known three-dimensional structures | Q34323005 | ||
| The PDBbind database: methodologies and updates | Q34424778 | ||
| Further development and validation of empirical scoring functions for structure-based binding affinity prediction | Q34526566 | ||
| Locating sweet spots for screening hits and evaluating pan-assay interference filters from the performance analysis of two lead-like libraries | Q34604133 | ||
| KRAS mutation testing in metastatic colorectal cancer | Q34643960 | ||
| Physiochemical drug properties associated with in vivo toxicological outcomes | Q34806480 | ||
| K-Ras4A splice variant is widely expressed in cancer and uses a hybrid membrane-targeting motif | Q35031435 | ||
| Drugging the undruggable RAS: Mission possible? | Q35163434 | ||
| Mutated BRAF Emerges as a Major Effector of Recurrence in a Murine Melanoma Model After Treatment With Immunomodulatory Agents | Q35534823 | ||
| Small-molecule library screening by docking with PyRx | Q35548740 | ||
| FAF-Drugs3: a web server for compound property calculation and chemical library design. | Q35604907 | ||
| Pioglitazone, an anti-diabetic drug requires sustained MAPK activation for its anti-tumor activity in MCF7 breast cancer cells, independent of PPAR-γ pathway | Q35882837 | ||
| Drug bioactivation, covalent binding to target proteins and toxicity relevance | Q36061821 | ||
| A comprehensive listing of bioactivation pathways of organic functional groups | Q36173107 | ||
| Development of new 5-(chromene-3-yl)methylene-2,4-thiazolidinediones as antimicrobial agents | Q36649317 | ||
| Structural modifications of (Z)-3-(2-aminoethyl)-5-(4-ethoxybenzylidene)thiazolidine-2,4-dione that improve selectivity for inhibiting the proliferation of melanoma cells containing active ERK signaling | Q36872318 | ||
| Mechanisms of chemical carcinogenicity and mutagenicity: a review with implications for predictive toxicology | Q37832235 | ||
| Structural alert/reactive metabolite concept as applied in medicinal chemistry to mitigate the risk of idiosyncratic drug toxicity: a perspective based on the critical examination of trends in the top 200 drugs marketed in the United States | Q37894080 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 4 | |
| P921 | main subject | colorectal cancer | Q188874 |
| P577 | publication date | 2019-03-31 | |
| P1433 | published in | Medicina | Q26842055 |
| P1476 | title | 5-Arylidene(chromenyl-methylene)-thiazolidinediones: Potential New Agents against Mutant Oncoproteins K-Ras, N-Ras and B-Raf in Colorectal Cancer and Melanoma | |
| P478 | volume | 55 |
| Q92447468 | STAT3 Relays a Differential Response to Melanoma-Associated NRAS Mutations | cites work | P2860 |
Search more.